-
1.发明公开
公开(公告)号：EP3366307A1
公开(公告)日：2018-08-29
申请号：EP18158799.9
申请日：2013-04-05
CPC分类号： C07K16/40 , A61K39/3955 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/54 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In another aspect, the invention provides methods and compositions for increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.
-
2.发明授权METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION 有权VERFAHREN ZUR BEHANDLUNG VON DISSEMINITERTER INTRAVASALER KOAGULOPATHIE DURCH HEMMUNG MASP-2-ABHÄNGIGERKOMPLEMENTAKTIVIERUNG
公开(公告)号：EP2488203B1
公开(公告)日：2016-12-07
申请号：EP10824223.1
申请日：2010-10-15
发明人： SCHWAEBLE, Hans-Wilhelm , DUDLER, Thomas, A. , TEDFORD, Clark, E. , PARENT, James, B. , DEMOPULOS, Gregory, A.
IPC分类号： C07K16/40
CPC分类号： C07K16/40 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C07K2317/92 , C12Y304/21104
-
3.发明公开
公开(公告)号：EP3530288A3
公开(公告)日：2019-12-18
申请号：EP19165032.4
申请日：2005-06-09
发明人： SCHWAEBLE, Hans-Wilhelm , STOVER, Cordula M. , TEDFORD, Clark E. , PARENT, James B. , FUJITA, Teizo
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C 1 q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASp-2 inhibitory agent and a pharmaceutically acceptable carrier.
-
4.发明授权COMPOSITIONS AND METHODS OF INHIBTING MASP-1 AND/OR MASP-3 FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 有权抑制MASP-1和/或MASP-3治疗阵发性血红蛋白尿症的组合物和方法
公开(公告)号：EP2833907B1
公开(公告)日：2018-02-28
申请号：EP13798222.9
申请日：2013-04-05
CPC分类号： C07K16/40 , A61K39/3955 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/54 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In another aspect, the invention provides methods and compositions for increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.
-
5.发明公开COMPOSITIONS AND METHODS OF INHIBTING MASP-1 AND/OR MASP-3 FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 有权组合物和用于抑制方法MASP-1和/或MASP-3用于治疗阵发性夜间血红蛋白尿
公开(公告)号：EP2833907A2
公开(公告)日：2015-02-11
申请号：EP13798222.9
申请日：2013-04-05
IPC分类号： A61K39/00
CPC分类号： C07K16/40 , A61K39/3955 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/54 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3 -dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3 - dependent complement activation. In another aspect, the invention provides methods and compositions for increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.
-
6.发明公开METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION 有权佐治美麻醉麻醉师麻黄UNG UNG LE ANG IT UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG UNG
公开(公告)号：EP2007425A2
公开(公告)日：2008-12-31
申请号：EP07759500.7
申请日：2007-03-27
发明人： SCHWAEBLE, Hans-Wilhelm , STOVER, Cordula Margaret , TEDFORD, Clark E. , PARENT, James B. , FUJITA, Teizo
IPC分类号： A61K39/395 , C07K16/40
CPC分类号： C07K16/40 , A01K67/0276 , A01K2207/15 , A01K2217/00 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0375 , A61K39/395 , A61K49/0008 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C12N9/6408 , C12N9/6424 , C12Y304/21104 , Y10S514/912
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (Clq-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
摘要翻译： 一方面，本公开提供了抑制活体受试者中MASP-2依赖性补体活化的作用的方法。 所述方法包括向有需要的受试者施用一定量的有效抑制MASP-2依赖性补体活化的MASP-2抑制剂的步骤。 在一些实施方案中，MASP-2抑制剂抑制与MASP-2介导的替代补体通路活化相关的细胞损伤，同时保留免疫系统的经典（Clq依赖性）通路组分。 在另一方面，本公开提供了用于抑制凝集素依赖性补体活化的作用的组合物，其包含治疗有效量的MASP-2抑制剂和药学上可接受的载体。
-
公开(公告)号：EP3067067B1
公开(公告)日：2020-01-08
申请号：EP16164436.4
申请日：2007-03-27
发明人： SCHWAEBLE, Hans-Wilhelm , STOVER, Cordula Margaret , TEDFORD, Clark E. , PARENT, James B. , FUJITA, Teizo
IPC分类号： A61K39/395 , C07K16/40 , C07K14/47 , A01K67/027
-
8.发明公开
公开(公告)号：EP3530288A2
公开(公告)日：2019-08-28
申请号：EP19165032.4
申请日：2005-06-09
发明人： SCHWAEBLE, Hans-Wilhelm , STOVER, Cordula M. , TEDFORD, Clark E. , PARENT, James B. , FUJITA, Teizo
IPC分类号： A61K39/395 , A61P9/00 , A61K31/00 , A61K38/02 , C07K16/40
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C 1 q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASp-2 inhibitory agent and a pharmaceutically acceptable carrier.
-
9.发明公开
公开(公告)号：EP3525798A1
公开(公告)日：2019-08-21
申请号：EP17861108.3
申请日：2017-10-12
IPC分类号： A61K31/7105 , A61K39/00 , A61K39/395 , A61K45/00 , A61K48/00 , A61P7/00
-
公开(公告)号：EP2694108B1
公开(公告)日：2018-06-06
申请号：EP12767899.3
申请日：2012-04-06
IPC分类号： A61K39/395 , C12N15/11 , C07K16/40
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.035 秒)
